medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 1

<< Back Next >>

Ann Hepatol 2018; 17 (1)

The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers

Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Qi X, Méndez-Sánchez N

Language: English
References: 41
Page: 14-17
PDF size: 124.31 Kb.


ABSTRACT

The early diagnosis of primary sclerosing cholangitis, hepatocellular carcinoma, and cholangiocarcinoma is often challenging. In a recent study in 134 patients (Arbelaiz, Hepatology 2017; 66: 1125-43), it was reported that specific proteins found in serum extracellular vesicles of patients with primary sclerosing cholangitis, hepatocellular carcinoma, or cholangiocarcinoma may be useful as noninvasive diagnostic and prognostic tools. This current article critically appraises this study.


REFERENCES

  1. Zhu RX, Seto W-K, Lai C-L, Yuen M-F. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016; 3: 332-9.

  2. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015; 2: 221-32.

  3. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 5: 1590-9.

  4. Chinchilla-López P, Aguilar-Olivos NE, García-Gómez J, Hernández-Alejandro KK, Chablé-Montero F, Motola-Kuba D, Patel T, et al. Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma. Ann Hepatol 2017; 4: 565-8.

  5. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 5: 261-80.

  6. Mittal S, El-Serag HB. Epidemiology of HCC: consider the population. J Clin Gastroenterol 2013; 47: S2-S6.

  7. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang Y, Wiangnon S, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma - focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 2010; 5: 1159-66.

  8. Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano- Rodriguez G, Almeda-Valdés P, González D, Uribe M. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 1: 52-5.

  9. Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez- Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 1: 16-24.

  10. Méndez-Sánchez N, Zamora-Valdés D, Vásquez-Fernández F, Uribe M. Hepatocellular carcinoma in Hispanics. Ann Hepatol 2007; 6: 279-80.

  11. Méndez-Sánchez N, Villa AR, Vázquez-Elizondo G, Ponciano- Rodríguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol 2008; 3: 226-9.

  12. Kikuchi L, Oliveira CP, Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Bio Med Res Int 2014; 2014: 106247.

  13. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 6: 1264-73.

  14. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; 2: 77-82.

  15. Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RMJ. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. Natl Cancer Inst 2006; 12: 873-5.

  16. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R. AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis 2010; 7: 490-5.

  17. Wood R, Brewster DH, Fraser LA, Brown H, Hayes PC, Garden OJ. Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. Eur J Cancer 2003; 14: 2087-92.

  18. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol 2010; 11: 407-16.

  19. Muńoz N, Bosch X. Epidemiology of hepatocellular carcinoma. In Okuda, K, Ishak KG (Eds.). Neoplasms of the Liver. New York: Springer; 1987, pp. 3-19.

  20. Muir C, Waterhouse J, Mack T. Cancer Incidence in Five Continents. Vol. 5. Lyon: IARC Publications; 1987, pp. 218-26.

  21. Tabor E, Di Bisceglie AM, Purcell RH. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in America. Houston, TX: Gulf Publishing Co., 1991.

  22. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.

  23. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, et al. SEER Cancer Statistics Review, 1975- 2014. Bethesda, MD: National Cancer Institute; 2017. Available from: http://seer.cancer.gov/csr/1975_2014/ [Accesed: November 2017]. Based on November 2016 SEER data submission, posted to the SEER web site, April 2017.

  24. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006; 1: 42-51.

  25. Yurkiewicz S. PBC patients face high wait-list mortality – consider allocation of exception MELD points to primary biliary cirrhosis patients on transplant list. New York: MedPage Today; 2015. Available from: https:// www.medpagetoday.com/clinical-context/pbcnash/51592.

  26. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 1971; 5784: 408-11.

  27. Van Beers BE. Diagnosis of cholangiocarcinoma. HPB? (Oxford) 2008; 2: 87-93.

  28. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ, et al. Diagnosis and management of primary sclerosingcolangitis. Hepatology 2010; 2: 660-78.

  29. Yao D, Kunam VK, Li X. A review of the clinical diagnosis and therapy of cholangiocarcinoma. J Int Med Res 2014; 1: 3-16.

  30. Thorburn D. Prognostic scores and non-invasive markers in primary sclerosing cholangitis: good for patients or for papers? Lancet Gastroenterol Hepatol 2017; 11: 774-6.

  31. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 12: 1632-51.

  32. Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomark Cancer 2017; 9: 1-9.

  33. Yin H, Tan Z, Wu J, Zhu J, Shedden KA, Marrero J, Lubman DM. Mass-selected site-specific core-fucosylation of serum proteins in hepatocellular carcinoma. J Proteome Res 2015; 11: 4876-84.

  34. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 2: 470-7.

  35. Wang B, Chen L, Chang HT. Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile. Biomark Med 2016; 6: 613-9.

  36. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.

  37. Stinton LM, Bentow C, Mahler M, Norman GL, Eksteen B, Mason AL, Kaplan GG, et al. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). PLoS One 2014; 11: e112877.

  38. Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Lapitz A, Perugorria MJ, Erice O, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2017; 4: 1125-43.

  39. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, László V, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2016; 16: 2667-88.

  40. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cellderived exosomes. Nat Med 1998; 5: 594-600.

  41. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 4: 373-83.




2020     |     www.medigraphic.com